Interested In Abbott India's (NSE:ABBOTINDIA) Upcoming ₹475.00 Dividend? You Have Three Days Left

It looks like Abbott India Limited (NSE:ABBOTINDIA) is about to go ex-dividend in the next 3 days. The ex-dividend date generally occurs two days before the record date, which is the day on which shareholders need to be on the company's books in order to receive a dividend. The ex-dividend date is important as the process of settlement involves at least two full business days. So if you miss that date, you would not show up on the company's books on the record date. This means that investors who purchase Abbott India's shares on or after the 25th of July will not receive the dividend, which will be paid on the 12th of September.

The company's upcoming dividend is ₹475.00 a share, following on from the last 12 months, when the company distributed a total of ₹475 per share to shareholders. Based on the last year's worth of payments, Abbott India has a trailing yield of 1.4% on the current stock price of ₹34125.00. We love seeing companies pay a dividend, but it's also important to be sure that laying the golden eggs isn't going to kill our golden goose! We need to see whether the dividend is covered by earnings and if it's growing.

If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. Abbott India paid out 71% of its earnings to investors last year, a normal payout level for most businesses. That said, even highly profitable companies sometimes might not generate enough cash to pay the dividend, which is why we should always check if the dividend is covered by cash flow. It paid out 91% of its free cash flow in the form of dividends last year, which is outside the comfort zone for most businesses. Companies usually need cash more than they need earnings - expenses don't pay themselves - so it's not great to see it paying out so much of its cash flow.

Abbott India paid out less in dividends than it reported in profits, but unfortunately it didn't generate enough cash to cover the dividend. Were this to happen repeatedly, this would be a risk to Abbott India's ability to maintain its dividend.

Check out our latest analysis for Abbott India

Click here to see the company's payout ratio, plus analyst estimates of its future dividends.

historic-dividend
NSEI:ABBOTINDIA Historic Dividend July 21st 2025
Advertisement

Have Earnings And Dividends Been Growing?

Stocks in companies that generate sustainable earnings growth often make the best dividend prospects, as it is easier to lift the dividend when earnings are rising. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. For this reason, we're glad to see Abbott India's earnings per share have risen 19% per annum over the last five years. Earnings have been growing at a decent rate, but we're concerned dividend payments consumed most of the company's cash flow over the past year.

Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. Abbott India has delivered 31% dividend growth per year on average over the past 10 years. It's great to see earnings per share growing rapidly over several years, and dividends per share growing right along with it.

The Bottom Line

Is Abbott India an attractive dividend stock, or better left on the shelf? Earnings per share growth is a positive, and the company's payout ratio looks normal. However, we note Abbott India paid out a much higher percentage of its free cash flow, which makes us uncomfortable. Overall, it's hard to get excited about Abbott India from a dividend perspective.

However if you're still interested in Abbott India as a potential investment, you should definitely consider some of the risks involved with Abbott India. To help with this, we've discovered 2 warning signs for Abbott India (1 is concerning!) that you ought to be aware of before buying the shares.

Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NSEI:ABBOTINDIA

Abbott India

Operates as a pharmaceutical company in India.

Flawless balance sheet 6 star dividend payer.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5361.6% undervalued
143 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
DE
Degen_GCR
P logo
Degen_GCR on Everpure ·

Second order memory play likely to double in a year

Fair Value:US$18054.9% undervalued
27 users have followed this narrative
1 users have commented on this narrative
17 users have liked this narrative
DO
Double_Bubbler
LUNR logo
Double_Bubbler on Intuitive Machines ·

Intuitive Machines: To The Moon and Beyond!

Fair Value:US$42.319.9% undervalued
15 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
YI
APP logo
yiannisz on AppLovin ·

AppLovin’s AI Engine Is Printing Profit

Fair Value:US$989.2449.4% undervalued
33 users have followed this narrative
2 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

KA
kapirey
PGHN logo
kapirey on Partners Group Holding ·

Partners Group Holding will achieve an 8.14% revenue rise over the next 5 years

Fair Value:CHF 68030.3% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kapirey
COPN logo
kapirey on Cosmo ·

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Fair Value:CHF 10023.8% undervalued
84 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kapirey
ALSTI logo
kapirey on STIF Société anonyme ·

Niche global leader in BESS explosion protection

Fair Value:€6014.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8590.6% undervalued
111 users have followed this narrative
2 users have commented on this narrative
31 users have liked this narrative
TR
tripledub
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$74017.0% undervalued
39 users have followed this narrative
3 users have commented on this narrative
33 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$268.6116.1% undervalued
1185 users have followed this narrative
7 users have commented on this narrative
34 users have liked this narrative